SCHEMBL4352328

SCHEMBL4352328

Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)P(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 4/20 0.61
P2RY1 P47900 4/20 0.61
P2RY2 P41231 3/20 0.61
SRC P12931 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
DNPH1 O43598 1/20 0.61
PRKAB2 O43741 1/20 0.61
TRPM2 O94759 1/20 0.61
LDHA P00338 1/20 0.61
ADRB2 P07550 1/20 0.61
FBP1 P09467 1/20 0.61
ADORA1 P30542 1/20 0.61
PRKAG1 P54619 1/20 0.61
PRKAA2 P54646 1/20 0.61
PDE4D Q08499 1/20 0.61
KCNH2 Q12809 1/20 0.61
PRKAA1 Q13131 1/20 0.61
PDE3A Q14432 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.61
TAS1R1 Q7RTX1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27779375 1.00 AHCY (0.61) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL28192648 0.99 AHCY (0.60) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL8836012 0.89 AHCY (0.59) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL8835991 0.89 AHCY (0.59) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL1969793 0.89 P2RY2 (0.63) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL27938581 0.88 PRMT5 (0.49) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL27938577 0.88 PRMT5 (0.49) AHCYP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL397800 0.87 AHCY (0.68) AHCYSMN1; SMN2ADORA1HSP90B1HIF1A
SCHEMBL31680251 0.87 AHCY (0.68) AHCYSMN1; SMN2ADORA1HSP90B1HIF1A
SCHEMBL28624001 0.87 PRMT5 (0.48) AHCYP2RY1P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112625995-B Method for producing PAPS by whole cell catalysis 江南大学 2023-07-04 CN claimed
CN-116393108-A Super-hydrophilic flower-like boric acid affinity material and preparation method and application thereof 福州大学 2023-07-07 CN disclosed
CN-112625995-B Method for producing PAPS by whole cell catalysis 江南大学 2023-07-04 CN disclosed
CN-109936983-A For enhancing the new compositions of flavor 国际香料和香精公司 2019-06-25 CN disclosed
CN-103338775-B Methods of using human milk oligosaccharides to reduce the incidence of necrotizing enterocolitis in infants, toddlers, or children ABBOTT LABORATORIES (US) 2016-11-30 CN disclosed
CN-106011310-A Method for amplifying and/or detecting nucleic acids, kits and uses of said method 生物梅里埃公司 2016-10-12 CN disclosed
CN-105849248-A Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases 比奥波利斯有限公司 2016-08-10 CN disclosed
CN-105007758-A Low-buffer nutritional composition and uses thereof MJN US HOLDINGS LLC 2015-10-28 CN disclosed
CN-104844687-A Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof BAYER IP GMBH 2015-08-19 CN disclosed
CN-104561239-A ATP (adenosine triphosphate) detection system SHANGHAI MANYI TECHNOLOGY CO LTD 2015-04-29 CN disclosed
CN-104126749-A Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk NESTEC SA 2014-11-05 CN disclosed
CN-103929980-A Infant formula with high SN-2 palmitate and oligofructose NESTEC SA 2014-07-16 CN disclosed
CN-103338775-A Methods of using human milk oligosaccharides to reduce the incidence of necrotizing enterocolitis in infants, toddlers, or children ABBOTT LAB 2013-10-02 CN disclosed
CN-101654712-A Method for testing sequence of nucleic acid single molecule UNIV SHANGHAI JIAOTONG 2010-02-24 CN disclosed
US-20090274686-A1 NUCLEOSIDE PHOSPHONATE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090186358-A1 Pathway Analysis of Cell Culture Phenotypes and Uses Thereof WYETH (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274686-A1 NUCLEOSIDE PHOSPHONATE DERIVATIVES ENTPD5, PNP, TYMP AHCY 379/4885P2RY1 251/4885P2RY2 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.